Four years after partnering with GammaDelta Therapeutics to develop therapies for solid tumors, Takeda Pharmaceutical pulled the trigger and exercised its option to acquire the London-based company.

Adicet Bio Inc., a biopharmaceutical company focused on the development of cancer therapies using gamma delta T cells, raised $80 million in private funding.